Clinical Dialogues™ in Multiple Myeloma
Curative vs Disease Control Approach in Multiple Myeloma CME, CPE Shaji Kumar, MD; P. Leif Bergsagel, MD; Frits van Rhee, MD, PhD | ||
Release Date: March 24, 2014 Expiration Date: March 24, 2015 | ||
Reviewed: January 17, 2017 for clinical relevance; CE is expired. Join a discussion between world-renowned myeloma experts moderated by Dr. Shaji Kumar as he and his guests Dr. P. Leif Bergsagel and Dr. Frits van Rhee compare and contrast the curative versus disease control approach in terms of myeloma therapy selection, including the rationale underlying these clinical approaches. This discussion will focus on the newest diagnostic advances to assess disease burden, as well as the limits of cytogenetics, FISH, and additional gene expression profiling tests in terms of their prognostic and predictive value.Provided by MediCom Worldwide, Inc. This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Celgene Corporation. | ||
What Are the Barriers to Optimal Care? CME, CPE Kenneth C. Anderson, MD; Beth Faiman, PhDc, RN, MSN, APRN-BC, AOCN®; Benyam Muluneh, PharmD, BCOP, CPP | ||
Release Date: February 12, 2014 Expiration Date: February 12, 2015 | ||
Reviewed: January 17, 2017 for clinical relevance; CE is expired. Join Kenneth Anderson, MD, Benyam Muluneh, PharmD, BCOP, CPP, and Beth Faiman, PhDc, RN, MSN, APRN-BC, AOCN, in a discussion of ongoing efforts to address new and emerging barriers to improving care including strategies to detect and achieve minimal residual disease in patients, monitoring adherence to oral therapies, survivorship planning, and related issues as multiple myeloma transitions to one more characteristic of a chronic disease with patients living longer.Provided by MediCom Worldwide, Inc. This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Celgene Corporation. | ||